TrialBritish journal of cancer2019

Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma.

Heinz Ludwig et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.